Inhaled corticosteroids and the risk of pneumonia in Medicare patients with COPD

References

• Chronic obstructive pulmonary disease (COPD). World Health Organization (WHO), November 2011. Available at: http://www.who.int/mediacentre/factsheets/fs315/en/index.html [Last accessed 6 February 2012]
   Google Scholar
• Kochanek K, Xu J, Murphy S, et al. Deaths: Preliminary Data for 2009. Hyattsville, MD: National Center for Health Statistics, 2011
   Google Scholar
• Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir 2004;23:932-46
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Global Initiative for Chronic Obstructive Lung Disease (GOLD), 2011. Available at: http://www.goldcopd.org/Guidelineitem.asp?l1=2&l2=1&intId=989 [Last accessed 17 March 2011]
   Google Scholar
• Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2010;5:189-95
   PubMedGoogle Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89
   PubMed Web of Science ®Google Scholar
• Spencer S, Evans DJ, Karner C, Cates CJ. Inhaled corticosteroids versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011;preprint(10):CD007033
   Google Scholar
• Ernst P, Gonzalez AV, Brassard P, Suissa S. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med 2007;176:162-6
   PubMed Web of Science ®Google Scholar
• Sharma G, Hanania NA, Shim YM. The aging immune system and its relationship to the development of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009;6:573-80
   PubMedGoogle Scholar
• Joo MJ, Au DH, Fitzgibbon ML, Lee TA. Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD. Respir Med 2010;104:246-52
   PubMed Web of Science ®Google Scholar
• Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet 2009;374:712-19
   PubMed Web of Science ®Google Scholar
• Hennessy S, Bilker WB, Berlin JA, Strom BL. Factors influencing the optimal control-to-case ratio in matched case-control studies. Am J Epidemiol 1999;149:195-7
   PubMed Web of Science ®Google Scholar
• Taylor JM. Choosing the number of controls in a matched case-control study, some sample size, power and efficiency considerations. Stat Med 1986;5:29-36
   PubMed Web of Science ®Google Scholar
• Inhaled Steroids Approximate Dose Conversions for Adults. GRIPA, 2005. Available at: http://gripa.org/Documents/Pharmacy-tidbits/Steroid-Inhaler-Conversion-Chart-12-05-Pharmacy-Tidbit.pdf [Last accessed 22 December 2005]
   Google Scholar
• Taylor JD. COPD and the response of the lung to tobacco smoke exposure. Pulm Pharmacol Ther 2010;23:376-83
   PubMed Web of Science ®Google Scholar
• Fleiss J, Levin B, Paik M. Statistical Methods for Rates and Proportions, 3rd edn. Hoboken, NJ: Wiley, 2003
   Google Scholar
• PN3a—Blood cultures performed within 24 hours prior to or 24 hours after hospital arrival for patients who were transferred or admitted to the ICU within 24 hours of hospital arrival. Quality Position Statements. Center for Medicaid and Medicare Services (CMS), 2008. Available at: http://www.qualityforum.org/QPS/MeasureDetails.aspx?standardID=343&print=0 [Last accessed 7 February 2012]
   Google Scholar
• Freedman DA, Berk RA. Weighting regressions by propensity scores. Eval Rev 2008;32:392-409
   PubMed Web of Science ®Google Scholar
• Akazawa M, Biddle AK, Stearns SC. Economic assessment of early initiation of inhaled corticosteroids in chronic obstructive pulmonary disease using propensity score matching. Clin Ther 2008;30 Spec No:1003-16
   PubMed Web of Science ®Google Scholar
• Hanania NA. The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther 2008;21:540-50
   PubMed Web of Science ®Google Scholar
• Health Cost and Utilization Project (HCUP). Agency for Healthcare Research and Quality (AHRQ), 2012. Available at: http://hcupnet.ahrq.gov/HCUPnet.jsp [Last accessed 14 March 2012]
   Google Scholar
• Singanayagam A, Chalmers JD, Hill AT. Inhaled corticosteroids and risk of pneumonia: evidence for and against the proposed association. QJM 2010;103:379-85
   PubMed Web of Science ®Google Scholar
• Malo de Molina R, Mortensen EM, Restrepo MI, et al. Inhaled corticosteroid use is associated with lower mortality for subjects with COPD and hospitalised with pneumonia. Eur Respir J 2010;36:751-7
   PubMed Web of Science ®Google Scholar
• Singanayagam A, Chalmers JD, Akram AR, Hill AT. Impact of inhaled corticosteroid use on outcome in COPD patients admitted with pneumonia. Eur Respir J 2011;38:36-41
   PubMed Web of Science ®Google Scholar
• Drummond M, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA, 2008;300:2407-16
   PubMed Web of Science ®Google Scholar